IMRN News and Press, Immuron Limited From 07/07/22

MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that...

Key Points US Naval Medical Research Centre (NMRC) submits IND application to the U.S. Food and Drug administration (FDA) Two human phase II clinical trials to be conducted. One trial will focus on the ability of the hyperimmune product to prevent infectious ...

UPDATE Key Points Manufacture Completed of investigational medical products to be clinically evaluated by the Uniformed Services University (USU). The clinical program aims to determine the comparative efficacy of Travelan ® with two third ...

Australia-based Immuron (NASDAQ:IMRN) appointed Steven Lydeamore as CEO, effective June 27. The company said Lydeamore recently served as CEO of Anatara Lifesciences. Immuron (IMRN) added that Jerry Kanellos, who has been interim CEO for the past two years will resume the role of COO fol...

MELBOURNE, Australia, May 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the a...

Key Highlights: North American Travelan ® sales up by 185% YoY in Q3 FY22 Global sales up 216% YoY in Q3 FY22. YTD March 31, FY22 worldwide Travelan® sales reached AU $392K, increasing 340% YoY. MELBOURNE, Australia, April 27, 2022 (GLOB...

Key Highlights: Immuron’s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award’ Travelan Investigational New ...

MELBOURNE, Australia, March 16, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce the...

3 High Volume Penny Stocks For Your January Watchlist While trading penny stocks and blue chips has gotten off to a rough start this week, many investors are optimistic about the future. With the Dow Jones Industrial Average down by more than 500 points and the S&P 500 down by aroun...

MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that...